34246 Federal Register / Vol. 86, No. 122 / Tuesday, June 29, 2021 / Notices 

Dated: June 23, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13814 Filed 6–28–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIH Support for 

Conferences and Scientific Meetings (Parent 

R13 Clinical Trial Not Allowed). 

Date: July 26–28, 2021. 

Time: 7:30 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F21B, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maryam Feili-Hariri, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F21B, 

Rockville, MD 20852, (240) 669–5026, 

haririmf@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 23, 2021. 

Tyeshia M. Roberson, 

Program Analyst,Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–13815 Filed 6–28–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Adeno-Associated 

Virus Polynucleotides, Polypeptides 

and Virions 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Heart, Lung, and 

Blood Institute, an institute of the 

National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of 

an Exclusive, Sublicensable Patent 

License to consolidate co-owned rights 

to the inventions and the Patents and 

Patent Applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice to The Children’s Medical 

Research Institute, having a place of 

business in Westmead NSW, Australia. 

DATES: Only written comments and/or 

applications for a license that are 

received by the National Heart, Lung, 

and Blood Institute Office of 

Technology and Development on or 

before July 14, 2021 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application(s), inquiries, and 

comments relating to the contemplated 

license should be directed to: John R. 

DeVany, Technology Transfer Analyst, 

NHLBI Office of Technology Transfer 

and Development, Telephone: 301–594– 

2436; email: john.devany@nih.gov. 

SUPPLEMENTARY INFORMATION: 

The following and all continuing U.S. 

and foreign patents/patent applications 

thereof are the intellectual properties to 

be licensed under the prospective 

agreement: 

1. U.S. Provisional Patent Application No. 

62/331,188, filed May 3, 2016, entitled 

‘‘Adeno-Associated Virus Polynucleotides 

and Virions’’ [HHS Ref. No. E–156–2016–0– 

US–01]. 

2. Patent Cooperation Treaty Patent 

Application No. PCT/US2017/030808, filed 

May 3, 2017, entitled ‘‘Adeno-Associated 

Virus Polynucleotides and Virions’’ [HHS 

Ref. No. E–156–2016–0–PCT–02]. 

3. Australian National Phase Patent 

Application No. 2017261249, filed October 

30, 2018, entitled ‘‘Adeno-Associated Virus 

Polynucleotides and Virions’’ [HHS Ref. No. 

E–156–2016–0–AU–03]. 

4. U.S. Patent No. 10,882,886 issued 

January 5, 2021, entitled ‘‘Adeno-Associated 

Virus Polynucleotides and Virions’’ [HHS 

Ref. No. E–156–2016–0–US–04]. 

5. European National Phase Patent 

Application No. 17793239.9 filed December 

3, 2018, entitled ‘‘Adeno-Associated Virus 

Polynucleotides and Virions’’ [HHS Ref. No. 

E–156–2016–0–EP–05]. 

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America, Sydney 

Children’s Hospital Network, and the 

Children’s Medical Research Institute 

(CMRI), a co-owner of said rights, for 

commercial development and 

marketing. The prospective patent 

license will be for the purpose of 

consolidating the patent rights to CMRI. 

Consolidation of these co-owned rights 

is intended to expedite development of 

the invention, consistent with the goals 

of the Bayh-Dole Act codified as 35 

U.S.C. 200–212. The prospective patent 

license will be worldwide, exclusive, 

may be limited to those fields of use 

commensurate in scope with the patent 

rights, and will be sublicensable. 

The subject technology pertains to a 

‘‘fossilized’’ AAV-derived endogenous 

viral element (referred to as mAAV– 

EVE) within the germline of an ancient 

lineage of Australian marsupials. This 

novel AAV coat protein sequence of 

mAAV–EVE may provide the basis for 

recombinant AAV vectors with unique 

biological properties. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR 404. The 

prospective Exclusive Patent License 

will be royalty bearing and may be 

granted unless, within fifteen (15) days 

from the date of this published notice, 

the National Heart, Lung, and Blood 

Institute Office of Technology Transfer 

and Development receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR 404. 

Complete applications for a license 

that are timely filed in response to this 

notice will be treated as objections to 

this to the grant of the contemplated 

exclusive patent license. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. License applications 

submitted in response to this Notice 

will be presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 22, 2021. 

Bruce D. Goldstein, 

Director, Office of Technology Transfer and 

Development, National Heart, Lung, and 

Blood Institute. 

[FR Doc. 2021–13826 Filed 6–28–21; 8:45 am] 

BILLING CODE 4140–01–P 


lotter on DSK11XQN23PROD with NOTICES1